Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study - Takeaways - MDSpire

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study

  • By

  • Vlaisavljević, Nada

  • Milosevic, Ivana

  • Sekulić, Borivoj

  • Nikolić, Jelena

  • Tomić, Velimir

  • Savić, Aleksandar

  • May 11, 2026

  • 0 min

Share

  • 1

    Early disease progression within 18 months (POD18) is a significant predictor of overall survival in multiple myeloma patients.

  • 2

    POD18 occurred in 44.0% of newly diagnosed multiple myeloma patients during a median follow-up of 60 months.

  • 3

    POD18 demonstrated superior prognostic discrimination compared to progression within 24 months (POD24) in this study.

  • 4

    Early mortality within six months was observed in 17.9% of patients and correlated with advanced disease stage.

  • 5

    Integrating early disease progression with baseline comorbidity provides a framework for dynamic risk stratification in multiple myeloma.

Original Source(s)

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study

  • by Vlaisavljević, Nada , Milosevic, Ivana , Sekulić, Borivoj , Nikolić, Jelena , Tomić, Velimir , Savić, Aleksandar

  • May 11, 2026

Related Content

Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma

Editorial: Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review